Clinical trials
Age-Related Macular Degeneration clinical trials
Below are recruiting age-related macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 138 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06875245RecruitingPhase 4
Comparing 8-Week vs 12-Week Faricimab for Wet AMD
This trial compares two different schedules (8 weeks vs 12 weeks) for follow-up injections of faricimab in people who are starting treatment for wet AMD. It aims to see if a longer gap between doses works just as well as the shorter interval.
PragueAges Any age - NCT06899360Recruiting
Age-related macular degeneration progression study
This study tracks how age-related macular degeneration (AMD) progresses over time and looks at factors that might affect your vision and quality of life. By participating, you'll help researchers understand more about AMD and what might predict better or worse outcomes.
Udine, UDAges 50–120 - NCT06906003Recruiting
Vision rehab and depression in age-related macular degeneration
This trial tests whether visual rehabilitation can help improve both vision and mood in people with advanced dry age-related macular degeneration. It aims to understand the link between vision loss and depression.
Rome, ItalyAges 55 years+ - NCT06924021Recruiting
AMD Eye Image Library (ABID) Study
This study is creating a library of eye images to help doctors better diagnose age-related macular degeneration (AMD). You can join if you have healthy eyes or any stage of AMD that has never been treated.
Fargo, North DakotaAges 50 years+ - NCT07004361Recruiting
Ethics of gene therapy for wet AMD
This study explores the ethical questions around using gene therapy for wet age-related macular degeneration (AMD). It is not a treatment trial, but a discussion study for patients whose doctors might consider gene therapy as an option.
Nantes, NantesAges 18 years+ - NCT07015034Recruiting
Preventing vision loss in older adults with chronic conditions
This study tests a model to help general practitioners find older patients who may be at risk of vision loss. It aims to spot problems early so treatment can start sooner.
Copenhagen, Capital RegionAges 70 years+ - NCT07064759RecruitingPhase 3
Gene therapy injection for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
Scottsdale, ArizonaAges 50 years+ - NCT07069647Recruiting
AI screening for diabetic eye disease and macular degeneration
This trial tests if an AI tool can help detect diabetic retinopathy and age-related macular degeneration in older adults visiting family medicine or geriatric clinics. It aims to catch these eye conditions early, before they cause vision loss.
TaipeiAges 20 years+ - NCT07084883Recruiting
AI system for early AMD detection
This trial tests an AI system designed to catch early signs of late age-related macular degeneration (AMD) before it's diagnosed. It's for people who haven't yet been diagnosed with AMD or treated for retinal disease.
Richmond Hill, New YorkAges 50 years+ - NCT07135570Recruiting
My Eyes, My Light: Amar Chokh, Amar Alo
This trial is studying people living in Char Fasson, Bangladesh, to see who might have undiagnosed eye problems. It's a local screening program to catch eye issues early.
Char Fasson, BholaAges 35 years+ - NCT07158775RecruitingPhase 1/Phase 2
BS01 gene therapy for dry age-related macular degeneration
This trial tests a new gene therapy, BS01, given as an eye injection. It is for people with advanced dry age-related macular degeneration (AMD) that has caused geographic atrophy—damage to the central part of the retina. The study aims to see if the treatment is safe and can help slow vision loss.
Edison, New JerseyAges 50–85 - NCT07205887RecruitingPhase 2
Study of EYE103 for wet AMD or macular edema after BRVO
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
Scottsdale, ArizonaAges 18 years+ - NCT07235527Recruiting
Aflibercept biosimilar for wet age-related macular degeneration
This study tests a biosimilar version of aflibercept (a drug that blocks abnormal blood vessel growth) in people with wet age-related macular degeneration. It aims to see how well the treatment works in real life.
Istanbul, şişliAges 45–90 - NCT07249216Recruiting
Eye fluid study for wet AMD treatment response
This study looks at eye fluid from people with untreated wet AMD to find out why some don't respond well to standard injections. The goal is to improve future treatments.
SingaporeAges 50 years+ - NCT07308639Recruiting
Eye disease health data study in Germany
This study looks at health records in Germany to understand how many people have certain eye conditions like age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. It also tests new ways to use this information for research.
LeverkusenAges 18 years+ - NCT07330674RecruitingPhase 1
Safety study of ABF-101 in healthy people and AMD patients
This trial tests the safety of a new drug called ABF-101 in two groups: healthy volunteers (Part A and B) and people with age-related macular degeneration (AMD, Part C). If you join, you will help researchers understand how the drug affects the body and if it's safe enough to study further.
Dallas, TexasAges 18–50 - NCT07215234RecruitingPhase 1/Phase 2
Study of an injection for geographic atrophy in AMD
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
Peoria, ArizonaAges 60 years+ - NCT01866371Recruiting
High-detail eye scans for children and adults
This study tests a high-resolution imaging method that takes very detailed pictures of the retina (the light-sensing layer at the back of the eye). You might benefit by getting your eye health checked in a structured imaging study—if you’re able to comfortably complete the scan.
Philadelphia, PennsylvaniaAges 7 years+ - NCT01496625Recruiting
Biobank study for retinal diseases and comparison samples
This study collects and stores blood and eye-related medical information to help researchers better understand retinal diseases, including age-related macular degeneration and diabetic retinopathy. Your samples may also be used to compare people with retinal disease to people without it.
Bethesda, MarylandAges 2–120 - NCT02669953Recruiting
Aflibercept injections for persistent wet macular degeneration
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
ViennaAges 50 years+ - NCT02253030Recruiting
Eye scan study for newly diagnosed wet AMD
This study uses a special eye scan (OCT angiography) to look at new, abnormal blood vessel growth in people with wet age-related macular degeneration (wet AMD) who have not been treated yet. It may help researchers better understand the disease and how it changes over time.
Portland, OregonAges 50–100 - NCT03011541Recruiting
Stem cell treatment for damaged retina or optic nerve
This study looks at stem-cell treatment to help vision in adults whose retina or optic nerve damage is not expected to improve on its own. You may be a candidate if your eye exam shows documented, stable or slowly changing damage and you can safely complete follow-up eye visits.
Westport, ConnecticutAges 18 years+ - NCT07427160Recruiting
Study on best treatment for bleeding under the retina
This trial looks at whether the type of abnormal blood vessels under the retina affects how well a procedure (pneumatic displacement) works to move a macular hemorrhage (bleeding) out of the central vision area. It may help doctors choose the best approach for patients.
Trento, TrentoAges 50 years+ - NCT07434713Recruiting
Testing early response to Eylea 8mg for wet AMD
This study looks at how quickly fluid in the retina clears after starting treatment with a higher dose of Eylea (aflibercept 8mg) for wet age-related macular degeneration (AMD). It aims to understand if early fluid changes can predict long-term outcomes.
BernAges 50 years+
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for age-related macular degeneration?
- Yes. Clin2 currently lists 138 recruiting age-related macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a age-related macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a age-related macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
- Wet Age-related Macular Degeneration (wAMD)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.